DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53

Table 2 Correlation between DRAM2 expressiom and clinicopathological factors in 259 NSCLC patients

Clinicopathological factors	Number of patient	DRAM2 negative or weak expression	DRAM2 over expression	P
Gender
Male	163	59	104	0.498
Female	96	30	66	0.498
Age
> 60	121	41	80	0.896
≤ 60	138	48	90	0.896
Histology
Squamous cell carcinoma	103	37	66	0.69
Adenocarcinoma	156	52	104	0.69
Differentiation
Well	118	43	75	0.599
Moderate-Poor	141	46	95	0.599
Lymph node metastasis
Negative	148	59	89	0.035
Positive	111	30	81	0.035
TNM stage
I	114	48	66	0.025
II + III	145	41	104	0.025

ISSN: 1756-9966